Gold‐standard evidence and best practice guidance for menstrual cycle‐informed clinical care: An overview for clinicians

Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment. Design Narrative, clinically oriented review. Methods We integrated findings from experimental, longitudinal and clinical studies on menstrual cycle physiology, hormone sensitivity, PMDD and PME, with a focus on evidence relevant to psychological practice. Emphasis was placed on gold‐standard methodologies (e.g., prospective symptom assessment, biologically anchored cycle phase determination) and on translational relevance for clinical decision‐making. Results A substantial minority of naturally cycling individuals show sensitivity to normative hormonal fluctuations, resulting in clinically significant distress or impairment. PMDD affects approximately 3–8% of menstruating individuals and is characterissed by severe, luteal‐phase–specific symptoms and elevated suicidality risk. PME appears even more prevalent, affecting up to 50–60% of individuals with mood disorders. Despite this, menstrual cycle‐related symptom patterns are rarely assessed or incorporated into routine care. The literature supports several key clinical strategies: (1) prospective daily symptom tracking across at least two menstrual cycles; (2) cycle‐informed case formulations integrating timing and symptom expression; and (3) adaptation of evidence‐based interventions to predictable cyclical patterns. Clinician‐ready tools and case‐based approaches facilitate implementation. Conclusions The menstrual cycle represents a clinically meaningful yet underrecognized source of within‐person variability in mental health. Integrating cycle‐informed approaches into psychological care can enhance diagnostic precision, improve personalized formulations and optimize treatment outcomes for individuals affected by PMDD and PME.